BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, Chinnaiyan P, Iliayas S, Chandrasekaran P, Navaneethapandian PD. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7:e47400. [PMID: 23251327 DOI: 10.1371/journal.pone.0047400] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 van Griensven J, Choun K, Chim B, Thai S, Lorent N, Lynen L. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. Trop Med Int Health 2015;20:1823-31. [PMID: 26426387 DOI: 10.1111/tmi.12609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
2 Tedla Z, Nguyen ML, Sibanda T, Nyirenda S, Agizew TB, Girde S, Rose CE, Samandari T. Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana. Chest 2015;147:1376-84. [PMID: 25340318 DOI: 10.1378/chest.14-0215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gersh JK, Barnabas RV, Matemo D, Kinuthia J, Feldman Z, Lacourse SM, Mecha J, Warr AJ, Kamene M, Horne DJ. Pulmonary tuberculosis screening in anti-retroviral treated adults living with HIV in Kenya. BMC Infect Dis 2021;21:218. [PMID: 33632173 DOI: 10.1186/s12879-021-05916-z] [Reference Citation Analysis]
4 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
5 Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J Med Res 2011;134:850-65. [PMID: 22310818 DOI: 10.4103/0971-5916.92630] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
6 Dravid A, Natarajan K, Medisetty M, Gawali R, Mahajan U, Kulkarni M, Saraf C, Ghanekar C, Kore S, Rathod N, Dravid M. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India. BMC Infect Dis 2019;19:714. [PMID: 31409289 DOI: 10.1186/s12879-019-4361-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Lewis JJ, Fielding KL, Grant AD, Chihota VN, Popane F, Luttig M, Muller D, Coetzee L, Churchyard GJ. Eligibility for isoniazid preventive therapy in South African gold mines. PLoS One 2013;8:e81376. [PMID: 24244741 DOI: 10.1371/journal.pone.0081376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690. [PMID: 24835842 DOI: 10.1016/s0140-6736(14)60162-8] [Cited by in Crossref: 150] [Cited by in F6Publishing: 98] [Article Influence: 21.4] [Reference Citation Analysis]
9 Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, Carrou JL, Kouame GM, Ouattara E, Messou E, Anzian A, Minga A, Gnokoro J, Gouesse P, Emieme A, Toni TD, Rabe C, Sidibé B, Nzunetu G, Dohoun L, Yao A, Kamagate S, Amon S, Kouame AB, Koua A, Kouamé E, Daligou M, Hawerlander D, Ackoundzé S, Koule S, Séri J, Ani A, Dembélé F, Koné F, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatunde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Karcher S, Rouzioux C, Kouame A, Assi R, Bakayoko A, Domoua SK, Deschamps N, Aka K, N'Dri-Yoman T, Salamon R, Journot V, Ahibo H, Ouassa T, Menan H, Inwoley A, Danel C, Eholié SP, Anglaret X; Temprano ANRS 12136 Study Group. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health 2017;5:e1080-9. [PMID: 29025631 DOI: 10.1016/S2214-109X(17)30372-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 42] [Article Influence: 24.0] [Reference Citation Analysis]
10 Durovni B, Cavalcante S. Preventive therapy for HIV-associated tuberculosis. Curr Opin HIV AIDS 2018;13:507-11. [PMID: 30286041 DOI: 10.1097/COH.0000000000000504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Den Boon S, Matteelli A, Ford N, Getahun H. Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. AIDS 2016;30:797-801. [PMID: 26730567 DOI: 10.1097/QAD.0000000000000985] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
12 Ousley J, Soe KP, Kyaw NTT, Anicete R, Mon PE, Lwin H, Win T, Cristofani S, Telnov A, Fernandez M, Ciglenecki I. IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence. Public Health Action 2018;8:20-4. [PMID: 29581939 DOI: 10.5588/pha.17.0087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016;13:34. [PMID: 27708678 DOI: 10.1186/s12981-016-0118-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
14 Hofman S, Segers MM, Ghimire S, Bolhuis MS, Sturkenboom MG, Van Soolingen D, Alffenaar JW. Emerging drugs and alternative possibilities in the treatment of tuberculosis. Expert Opin Emerg Drugs 2016;21:103-16. [PMID: 26848966 DOI: 10.1517/14728214.2016.1151000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. BMJ Glob Health 2018;3:e001135. [PMID: 30364389 DOI: 10.1136/bmjgh-2018-001135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S297-305. [PMID: 25768869 DOI: 10.1097/QAI.0000000000000497] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
17 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69:1-11. [PMID: 32053584 DOI: 10.15585/mmwr.rr6901a1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 54.0] [Reference Citation Analysis]
18 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR, Crane CM, Burgos M, Lobue P, Winston CA, Belknap R. Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. Am J Transplant 2020;20:1196-206. [DOI: 10.1111/ajt.15841] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
19 Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Microbiol Spectr 2017;5. [PMID: 28233512 DOI: 10.1128/microbiolspec.TNMI7-0028-2016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
20 Mickenautsch S, Fu B, Gudehithlu S, Berger VW. Accuracy of the Berger-Exner test for detecting third-order selection bias in randomised controlled trials: a simulation-based investigation. BMC Med Res Methodol 2014;14:114. [PMID: 25283963 DOI: 10.1186/1471-2288-14-114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
21 DeLuca A, Dhumal G, Paradkar M, Suryavanshi N, Mave V, Kohli R, Shivakumar SVBY, Hulyolkar V, Gaikwad A, Nangude A, Pardeshi G, Kadam D, Gupta A. Addressing knowledge gaps and prevention for tuberculosis-infected Indian adults: a vital part of elimination. BMC Infect Dis 2018;18:202. [PMID: 29720095 DOI: 10.1186/s12879-018-3116-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
23 Swaminathan S, Chandrasekaran P. Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience. Expert Review of Anti-infective Therapy 2014;12:289-92. [DOI: 10.1586/14787210.2014.880338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Bracchi M, van Halsema C, Post F, Awosusi F, Barbour A, Bradley S, Coyne K, Dixon-Williams E, Freedman A, Jelliman P, Khoo S, Leen C, Lipman M, Lucas S, Miller R, Seden K, Pozniak A. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. HIV Med 2019;20 Suppl 6:s2-s83. [PMID: 31152481 DOI: 10.1111/hiv.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]